CNBX Pharmaceuticals Inc. (CNBX)
USD 0.01
(5.93%)
USD 0.01
(5.93%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 410.16 Thousand USD | 247.18% |
| 2022 | -168.56 Thousand USD | 23.7% |
| 2021 | -220.92 Thousand USD | -3186.85% |
| 2020 | 7157.00 USD | -27.29% |
| 2019 | 9843.00 USD | 2.53% |
| 2018 | 9600.00 USD | 819.1% |
| 2017 | -1335.00 USD | -101.19% |
| 2016 | 112.5 Thousand USD | 0.0% |
| 2015 | - USD | 0.0% |
| 2014 | - USD | 100.0% |
| 2013 | -58.11 Thousand USD | -3417.62% |
| 2012 | -1652.00 USD | 98.86% |
| 2011 | -144.41 Thousand USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| 2005 | - USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 1558.00 USD | -96.88% |
| 2024 Q1 | 49.97 Thousand USD | -18.75% |
| 2024 Q3 | 17.57 Thousand USD | 1027.73% |
| 2023 Q1 | -43.18 Thousand USD | -149.19% |
| 2023 Q4 | 61.5 Thousand USD | -77.23% |
| 2023 FY | 248.1 Thousand USD | 247.18% |
| 2023 Q2 | -40.39 Thousand USD | 6.47% |
| 2023 Q3 | 270.17 Thousand USD | 768.91% |
| 2022 Q3 | -48.82 Thousand USD | 3.48% |
| 2022 FY | -168.56 Thousand USD | 23.7% |
| 2022 Q1 | -51.82 Thousand USD | -1.67% |
| 2022 Q2 | -50.58 Thousand USD | 2.38% |
| 2022 Q4 | -17.33 Thousand USD | 64.51% |
| 2021 Q4 | -50.97 Thousand USD | 8.89% |
| 2021 FY | -220.92 Thousand USD | -3186.85% |
| 2021 Q1 | - USD | -100.0% |
| 2021 Q2 | - USD | 0.0% |
| 2021 Q3 | -55.94 Thousand USD | 0.0% |
| 2020 FY | 7157.00 USD | -27.29% |
| 2020 Q3 | 1890.00 USD | 44.27% |
| 2020 Q2 | 1310.00 USD | -25.31% |
| 2020 Q1 | 1754.00 USD | -14.77% |
| 2020 Q4 | 5271.00 USD | 178.89% |
| 2019 FY | 9843.00 USD | 2.53% |
| 2019 Q3 | 2160.00 USD | -6.9% |
| 2019 Q1 | 3305.00 USD | 11.81% |
| 2019 Q2 | 2320.00 USD | -29.8% |
| 2019 Q4 | 2058.00 USD | -4.72% |
| 2018 Q1 | 1758.00 USD | -38.75% |
| 2018 Q4 | 2956.00 USD | 0.0% |
| 2018 FY | 9600.00 USD | 819.1% |
| 2018 Q3 | 2956.00 USD | 53.08% |
| 2018 Q2 | 1931.00 USD | 9.84% |
| 2017 Q1 | - USD | -100.0% |
| 2017 Q4 | 2870.00 USD | 82.69% |
| 2017 Q3 | 1571.00 USD | 26.39% |
| 2017 FY | -1335.00 USD | -101.19% |
| 2017 Q2 | 1243.00 USD | 0.0% |
| 2016 FY | 112.5 Thousand USD | 0.0% |
| 2016 Q3 | 50 Thousand USD | 400.0% |
| 2016 Q1 | - USD | 0.0% |
| 2016 Q2 | 10 Thousand USD | 0.0% |
| 2016 Q4 | 52.5 Thousand USD | 5.0% |
| 2015 Q2 | - USD | 0.0% |
| 2015 FY | - USD | 0.0% |
| 2015 Q4 | - USD | 0.0% |
| 2015 Q3 | - USD | 0.0% |
| 2015 Q1 | - USD | 0.0% |
| 2014 Q4 | - USD | 0.0% |
| 2014 Q3 | - USD | 100.0% |
| 2014 Q2 | -29.33 Thousand USD | -106.27% |
| 2014 Q1 | -14.22 Thousand USD | 75.52% |
| 2014 FY | - USD | 100.0% |
| 2013 Q2 | -4639.00 USD | 69.35% |
| 2013 Q1 | -15.13 Thousand USD | -816.28% |
| 2013 Q3 | -4712.00 USD | -1.57% |
| 2013 FY | -58.11 Thousand USD | -3417.62% |
| 2013 Q4 | -58.11 Thousand USD | -1133.26% |
| 2012 Q2 | -4286.00 USD | 58.16% |
| 2012 Q1 | -10.24 Thousand USD | 92.91% |
| 2012 Q3 | -4000.00 USD | 6.67% |
| 2012 Q4 | -1652.00 USD | 58.7% |
| 2012 FY | -1652.00 USD | 98.86% |
| 2011 Q1 | - USD | 0.0% |
| 2011 FY | -144.41 Thousand USD | 0.0% |
| 2011 Q4 | -144.41 Thousand USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q4 | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2006 Q2 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q1 | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2005 FY | - USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | -2439.00 USD | 16916.933% |
| Evofem Biosciences, Inc. | 11.7 Million USD | 96.496% |
| Nascent Biotech, Inc. | -319.5 Thousand USD | 228.374% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 119.1 Million USD | 99.656% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | -25.79 Million USD | 101.59% |
| ProtoKinetix, Incorporated | -48.25 Thousand USD | 949.924% |
| Skye Bioscience, Inc. | -124.25 Thousand USD | 430.11% |
| Eiger BioPharmaceuticals, Inc. | 14.99 Million USD | 97.265% |
| Nanobac Pharmaceuticals, Incorporated | 3102.00 USD | -13122.598% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 9.79 Million USD | 95.812% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -524.034% |
| Propanc Biopharma, Inc. | -34.15 Thousand USD | 1301.069% |
| Mesoblast Limited | -35.16 Million USD | 101.166% |
| Marizyme, Inc. | 457.7 Thousand USD | 10.386% |
| Genus plc | 178.7 Million USD | 99.77% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 220.1 Million USD | 99.814% |
| Therapeutic Solutions International, Inc. | 62.22 Thousand USD | -559.154% |
| Nymox Pharmaceutical Corporation | -11 Thousand USD | 3828.773% |
| ContraFect Corporation | -154 Thousand USD | 366.341% |
| PsyBio Therapeutics Corp. | -50 Thousand USD | 920.33% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -434.34% |
| IMV Inc. | -962.29 Thousand USD | 142.623% |
| AXIM Biotechnologies, Inc. | -387.5 Thousand USD | 205.849% |
| MultiCell Technologies, Inc. | 49.32 USD | -831540.308% |
| ONE Bio Corp. | 20.12 Million USD | 97.962% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 40.26 Million USD | 98.981% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -738.783% |
| Q BioMed Inc. | -8988.00 USD | 4663.474% |
| Emmaus Life Sciences, Inc. | 28.25 Million USD | 98.548% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | -15.42 Thousand USD | 2759.265% |
| American Oriental Bioengineering, Inc. | 44.35 Million USD | 99.075% |
| Provectus Biopharmaceuticals, Inc. | -1.14 Million USD | 135.93% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -485.95% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | -4952.00 USD | 8382.815% |
| Acro Biomedical Co., Ltd. | 140.5 Thousand USD | -191.932% |
| Curative Biotechnology, Inc. | -97.51 Thousand USD | 520.617% |
| GB Sciences, Inc. | -624.00 USD | 65831.571% |
| Alpha Cognition Inc. | -86.02 Thousand USD | 576.781% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 7.56 Billion USD | 99.995% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | -208.00 USD | 197294.712% |
| Enzolytics Inc. | 30.7 Thousand USD | -1235.694% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 482.43 Thousand USD | 14.98% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.1 Billion USD | 99.963% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | -514.51 Thousand USD | 179.72% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | 33.564% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Genscript Biotech Corporation | 409.55 Million USD | 99.9% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -8856.00 USD | 4731.493% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | -83.84 Thousand USD | 589.171% |
| Kadimastem Ltd | -630.13 Thousand USD | 165.091% |
| Helix BioMedix, Inc. | 987.98 Thousand USD | 58.485% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 9.61 Million USD | 95.732% |
| BioStem Technologies, Inc. | 15.42 Million USD | 97.341% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | -11.83 Thousand USD | 3565.695% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -132.309% |
| Regen BioPharma, Inc. | 176.56 Thousand USD | -132.309% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.35 Million USD | 69.777% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | -29 Thousand USD | 1514.362% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 450.04 Thousand USD | 8.861% |
| SYBLEU INC | 11.69 Thousand USD | -3406.883% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 4.6 Million USD | 91.099% |
| Bioxytran, Inc. | -8285.00 USD | 5050.694% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | - USD | -Infinity% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | -373 Thousand USD | 209.964% |
| Neutra Corp. | 14.33 Thousand USD | -2761.284% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 600.201% |
| PureTech Health plc | -1.6 Million USD | 125.587% |
| Coeptis Therapeutics, Inc. | -1 Million USD | 140.966% |
| IXICO plc | 3.27 Million USD | 87.457% |
| IntelGenx Technologies Corp. | -694 Thousand USD | 159.102% |
| Gelesis Holdings, Inc. | -1.79 Million USD | 122.901% |
| CSL Limited | 7.7 Billion USD | 99.995% |
| Cellectis S.A. | 18 Thousand USD | -2178.694% |